Burzynski Research Institute (BZYR) Return on Assets (2011 - 2025)
Burzynski Research Institute (BZYR) posted Return on Assets of 6.0% for Q4 2025, up 26.68% sequentially from 8.18% in Q3 2025, and up 448.0% YoY from 1.09% in Q4 2024.
Burzynski Research Institute (BZYR) Return on Assets (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Return on Assets for 15 years, with the latest figure at 6.0% in Q4 2025.
- Quarterly Return on Assets rose 448.0% year-over-year to 6.0% in Q4 2025, while the trailing twelve-month figure through Nov 2025 was 6.0% (up 448.0% YoY) and the FY2025 annual result came in at 8.78%, down 250.0% from the prior year.
- Return on Assets climbed to 6.0% in Q4 2025 per BZYR's latest filing, from 8.18% in the prior quarter.
- Over five years, Return on Assets peaked at 1.71% in Q1 2022 and troughed at 14.83% in Q1 2025.
- A 5-year average of 6.8% and a median of 7.23% in 2023 frame the typical range for Return on Assets.
- The sharpest annual moves came in 2021 and 2022: Return on Assets plunged 715 bps in 2021, then jumped 606 bps in 2022.
- Over 5 years, Return on Assets stood at 2.24% in 2021, then slumped by 124 bps to 5.01% in 2022, then slumped by 63 bps to 8.15% in 2023, then fell by 29 bps to 10.48% in 2024, then soared by 43 bps to 6.0% in 2025.
- According to Business Quant data, Return on Assets over the past three periods registered 6.0%, 8.18%, and 10.09% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.00% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.00% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.00% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.00% |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -6.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -6.00% |
| Aug 31, 2025 | -8.18% |
| May 31, 2025 | -10.09% |
| Feb 28, 2025 | -14.83% |
| Nov 30, 2024 | -10.48% |
| Aug 31, 2024 | -10.52% |
| May 31, 2024 | -8.15% |
| Feb 29, 2024 | -7.72% |
| Nov 30, 2023 | -8.15% |
| Aug 31, 2023 | -7.30% |
| May 31, 2023 | -6.54% |
| Feb 28, 2023 | -4.91% |
| Nov 30, 2022 | -5.01% |
| Aug 31, 2022 | -2.46% |
| May 31, 2022 | -1.76% |
| Feb 28, 2022 | -1.71% |
| Nov 30, 2021 | -2.24% |
| Aug 31, 2021 | -4.98% |
| May 31, 2021 | -7.17% |
| Feb 28, 2021 | -7.77% |